Table of Content

1 Markets
1.1 Product Definition
1.2 Inclusion and Exclusion Criteria
1.3 Market Scope
1.3.1 Scope of the Study
1.3.2 Key Questions Answered in the Report
1.4 Research Methodology
1.4.1 Global Acute Care Syndromic Testing Market: Research Methodology
1.4.2 Data Sources
1.4.2.1 Primary Data Sources
1.4.2.2 Secondary Data Sources
1.4.3 Market Estimation Model
1.4.4 Criteria for Company Profiling

2 Market Overview
2.1 Overview
2.2 Acute Care Syndromic Testing Workflow Analysis
2.3 Market Footprint and Growth Potential
2.4 Future Potential

3 Industry Insight
3.1 Stakeholder’s Perspective (N=20)
3.1.1 Physician’s Perception
3.1.2 Payor’s Perception
3.1.3 Investor’s Perception
3.2 Legal and Regulatory Framework of the Global Acute Care Syndromic Testing Market
3.2.1 Regulatory Framework in North America
3.2.1.1 The U.S.
3.2.1.2 Canada
3.2.2 Regulatory Framework in Europe
3.2.3 Regulatory Framework in Asia-Pacific
3.2.3.1 Japan
3.2.3.2 China
3.2.3.3 India
3.2.3.4 South Korea
3.2.3.5 Australia
3.2.4 Regulatory Framework in Latin America
3.2.4.1 Brazil
3.2.4.2 Mexico
3.2.5 Regulatory Framework in Rest-of-the-World
3.2.5.1 U.A.E.
3.2.5.2 K.S.A.
3.3 Product Benchmarking

4 Market Dynamics
4.1 Overview
4.2 Impact Analysis
4.3 Market Drivers
4.3.1 Faster Results Acquired with Syndromic Tests
4.3.2 Increasing Incidence of Infectious Diseases
4.3.3 Overall Reduced Cost of Care Due to Early Diagnosis with Syndromic Testing
4.3.4 Reduced Severe Adverse Effects from Pathogens
4.4 Market Challenges
4.4.1 Need for Better Policies with Respect to Acute Care Syndromic Test Reimbursement
4.4.2 Lack of High-Complexity Testing Centres
4.5 Market Opportunities
4.5.1 Quick Access to Treatment and Reduced Use of Antibiotics
4.5.2 High Number of Synergistic Activities and Mergers and Acquisitions (M&A) Over the Past Years

5 Competitive Insight
5.1 Overview
5.2 Key Strategies and Developments
5.2.1 Synergistic Activities
5.2.2 Product Launches and Product Approvals
5.2.3 Funding and Expansion
5.2.4 Mergers and Acquisitions
5.3 Market Share Analysis (2022)
5.4 Growth-Share Analysis (2022)
5.4.1 Growth-Share Analysis (by Disease Type)
5.4.2 Growth-Share Analysis (by Target)

6 Global Acute Care Syndromic Testing Market (By Disease Type), 2022-2033
6.1 Overview
6.2 Competitive Analysis
6.3 Respiratory Diseases
6.3.1 Upper Respiratory Tract Infections
6.3.2 Lower Respiratory Tract Infections
6.4 Gastrointestinal Diseases
6.5 Genitourinary Diseases
6.5.1 Urinary Tract Infections
6.5.2 Sexually Transmitted Diseases
6.6 Tropical Diseases
6.7 Others

7 Global Acute Care Syndromic Testing Market (By Target), 2022-2033
7.1 Overview
7.2 Bacteria
7.2.1 Gram-Positive Bacteria
7.2.2 Gram-Negative Bacteria
7.3 Viruses
7.4 Fungi
7.5 Parasites

8 Global Acute Care Syndromic Testing Market (By Sample Type), 2022-2033
8.1 Overview
8.2 Blood
8.3 Urine
8.4 Biofluids
8.4.1 Saliva
8.4.2 Sputum
8.5 Stool
8.6 Swabs
8.6.1 Genital Swabs
8.6.2 Nasopharyngeal Swabs
8.7 Other Sample Types

9 Global Acute Care Syndromic Testing Market (By End User), 2022-2033
9.1 Overview
9.2 Hospitals
9.3 Clinical and Diagnostic Laboratories
9.4 Research and Academic Institutions
9.5 Other End Users

10 Global Acute Care Syndromic Testing Market (By Region), 2022-2033
10.1 Overview
10.2 North America
10.2.1 North America Acute Care Syndromic Testing Market, By End User
10.2.2 North America Acute Care Syndromic Testing Market, By Country
10.2.2.1 U.S.
10.2.2.2 Canada
10.3 Asia-Pacific
10.3.1 Asia-Pacific Acute Care Syndromic Testing Market, By End User
10.3.2 Asia-Pacific Acute Care Syndromic Testing Market, By Country
10.3.2.1 China
10.3.2.2 Japan
10.3.2.3 India
10.3.2.4 Australia
10.3.2.5 South Korea
10.3.2.6 Rest-of-Asia-Pacific
10.4 Europe
10.4.1 Europe Acute Care Syndromic Testing Market, By End User
10.4.2 Europe Acute Care Syndromic Testing Market, By Country
10.4.2.1 Germany
10.4.2.2 France
10.4.2.3 U.K.
10.4.2.4 Italy
10.4.2.5 Spain
10.4.2.6 Rest-of-Europe
10.5 Latin America
10.5.1 Latin America Acute Care Syndromic Testing Market, By End User
10.5.2 Latin America Acute Care Syndromic Testing Market, By Country
10.5.2.1 Brazil
10.5.2.2 Mexico
10.5.2.3 Rest-of-Latin America
10.6 Rest-of-the-World
10.6.1 Rest-of-the-World Acute Care Syndromic Testing Market, By End User

11 Company Profiles
11.1 Overview
11.2 Acute Care Syndromic Testing Ecosystem Active Players
11.3 Abbott Laboratories
11.3.1 Company Overview
11.3.2 Role of Abbott Laboratories in the Global Acute Care Syndromic Testing Market
11.3.3 Financials
11.3.4 Recent Developments
11.3.4.1 Corporate Strategies
11.3.4.2 Business Strategies
11.3.5 Analyst Perspective
11.4 Becton, Dickinson and Company
11.4.1 Company Overview
11.4.2 Role of Becton, Dickinson and Company in the Global Acute Care Syndromic Testing Market
11.4.3 Financials
11.4.4 Recent Developments
11.4.4.1 Corporate Strategies
11.4.4.2 Business Strategies
11.4.5 Analyst Perspective
11.5 Biocartis NV
11.5.1 Company Overview
11.5.2 Role of Biocartis NV in the Global Acute Care Syndromic Testing Market
11.5.3 Financials
11.5.4 Recent Developments
11.5.4.1 Business Strategies
11.5.5 Analyst Perspective
11.6 bioM?rieux SA (BioFire Diagnostics)
11.6.1 Company Overview
11.6.2 Role of bioM?rieux SA (BioFire Diagnostics) in the Global Acute Care Syndromic Testing Market
11.6.3 Financials
11.6.4 Recent Developments
11.6.4.1 Business Strategies
11.6.5 Analyst Perspective
11.7 Danaher Corporation (Cepheid, Inc.)
11.7.1 Company Overview
11.7.2 Role of Danaher Corporation (Cepheid, Inc.) in the Global Acute Care Syndromic Testing Market
11.7.3 Financials
11.7.4 Recent Developments
11.7.4.1 Corporate Strategies
11.7.4.2 Business Strategies
11.7.5 Analyst Perspective
11.8 DiaSorin S.p.A (Luminex Corporation)
11.8.1 Company Overview
11.8.2 Role of DiaSorin S.p.A (Luminex Corporation) in the Global Acute Care Syndromic Testing Market
11.8.3 Financials
11.8.4 Recent Developments
11.8.4.1 Corporate Strategies
11.8.4.2 Business Strategies
11.8.5 Analyst Perspective
11.9 Eurofins Scientific (Eurofins Viracor)
11.9.1 Company Overview
11.9.2 Role of Eurofins Scientific (Eurofins Viracor) in the Global Acute Care Syndromic Testing Market
11.9.3 Financials
11.9.4 Recent Developments
11.9.4.1 Business Strategies
11.9.5 Analyst Perspective
11.1 Karius
11.10.1 Company Overview
11.10.2 Role of Karius in the Global Acute Care Syndromic Testing Market
11.10.3 Recent Developments
11.10.3.1 Business Strategies
11.10.4 Analyst Perspective
11.11 Laboratory Corporation of America Holdings.
11.11.1 Company Overview
11.11.2 Role of Laboratory Corporation of America Holdings. in the Global Acute Care Syndromic Testing Market
11.11.3 Financials
11.11.4 Analyst Perspective
11.12 QIAGEN N.V.
11.12.1 Company Overview
11.12.2 Role of QIAGEN N.V. in the Global Acute Care Syndromic Testing Market
11.12.3 Financials
11.12.4 Recent Developments
11.12.4.1 Business Strategies
11.12.5 Analyst Perspective
11.13 QuantuMDx Group Ltd.
11.13.1 Company Overview
11.13.2 Role of QuantuMDx Group Ltd. in the Global Acute Care Syndromic Testing Market
11.13.3 Recent Developments
11.13.3.1 Corporate Strategies
11.13.3.2 Business Strategies
11.13.4 Analyst Perspective
11.14 Seegene Inc.
11.14.1 Company Overview
11.14.2 Role of Seegene, Inc. in the Global Acute Care Syndromic Testing Market
11.14.3 Financials
11.14.4 Recent Developments
11.14.4.1 Corporate Strategies
11.14.4.2 Business Strategies
11.14.5 Analyst Perspective
11.15 Siemens Healthineers AG
11.15.1 Company Overview
11.15.2 Role of Siemens Healthineers AG in the Global Acute Care Syndromic Testing Market
11.15.3 Financials
11.15.4 Analyst Perspective
11.16 SpeeDx
11.16.1 Company Overview
11.16.2 Role of SpeeDX in the Global Acute Care Syndromic Testing Market
11.16.3 Analyst Perspective
11.17 Thermo Fisher Scientific Inc.
11.17.1 Company Overview
11.17.2 Role of Thermo Fisher Scientific Inc. in the Global Acute Care Syndromic Testing Market
11.17.3 Financials
11.17.4 Recent Developments
11.17.4.1 Business Strategies
11.17.5 Analyst Perspective
List of Figures
Figure 1: Global Acute Care Syndromic Testing Market, $Billion, 2023 and 2033
Figure 2: History of Known Pandemics
Figure 3: Incidence of Common Infectious Diseases in the U.S (Excluding Influenza), 2020
Figure 4: Global Acute Care Syndromic Testing Market (by Disease Type), Share (%), 2022 and 2033
Figure 5: Global Acute Care Syndromic Testing Market (by Target), Share (%), 2022 and 2033
Figure 6: Share of Global Acute Care Syndromic Testing Market (by Region), 2022
Figure 7: Share of Key Developments and Strategies, January 2020-June 2023
Figure 8: Global Acute Care Syndromic Testing Market (by Company), Share (%), 2022
Figure 9: Global Acute Care Syndromic Testing Market Segmentation
Figure 10: Global Acute Care Syndromic Testing Market: Research Methodology
Figure 11: Primary Research Methodology
Figure 12: Bottom-Up Approach (Segment-Wise Analysis)
Figure 13: Top-Down Approach (Segment-Wise Analysis)
Figure 14: Acute Care Syndromic Testing Workflow
Figure 15: Global Acute Care Syndromic Testing Market, $Billion, 2022-2033
Figure 16: Physician’s Perception on the Factors Affecting the Adoption of Acute Care Syndromic Testing
Figure 17: Global Acute Care Syndromic Testing Market Dynamics
Figure 18: Traditional Testing vs. Syndromic Testing
Figure 19: Incidence of Common Infectious Diseases in the U.S (Excluding Influenza), 2020
Figure 20: Incidence of Common Infectious Diseases in Germany (Excluding COVID-19), 2020
Figure 21: Incidence of Common Infectious Diseases in China, 2020
Figure 22: History of Known Pandemics
Figure 23: Examples of Cost Reductions
Figure 24: Time of Diagnosis vs. Disease Effect
Figure 25: Syndromic Panels Reimbursement Scenario in the U.S.
Figure 26: Syndromic Panels Reimbursement Scenario in Mexico
Figure 27: Reduction in Antibiotics Use with Syndromic Testing
Figure 28: Increasing Synergistic Activities of the Global Acute Care Syndromic Testing Market, January 2021-June 2023 (Number of Partnerships, Collaborations and Agreements)
Figure 29: Key Mergers and Acquisitions in the Global Acute Care Syndromic Testing Market
Figure 30: Share of Key Developments and Strategies, January 2020-June 2023
Figure 31: Share of Synergistic Activities (by Company), January 2020-June 2023
Figure 32: Number of Product Launches and Product Approvals (by Company), January 2020-June 2023
Figure 33: Number of Mergers and Acquisitions (by Company), January 2020-June 2023
Figure 34: Global Acute Care Syndromic Testing Market (by Company), Share (%), 2022
Figure 35: Global Acute Care Syndromic Testing Market, Growth-Share Matrix (by Disease Type), 2023-2033
Figure 36: Global Acute Care Syndromic Testing Market, Growth-Share Matrix (by Target), 2023-2033
Figure 37: Global Acute Care Syndromic Testing Market (by Disease Type)
Figure 38: Global Acute Care Syndromic Testing Market (by Disease Type), Share (%), 2022 and 2033
Figure 39: Global Acute Care Syndromic Testing Market (Respiratory Diseases), $Billion, 2022-2033
Figure 40: Global Acute Care Syndromic Testing Market (Upper Respiratory Tract Infections), $Billion, 2022-2033
Figure 41: Global Acute Care Syndromic Testing Market (Lower Respiratory Tract Infections), $Billion, 2022-2033
Figure 42: Global Acute Care Syndromic Testing Market (Gastrointestinal Diseases), $Billion, 2022-2033
Figure 43: Global Acute Care Syndromic Testing Market (Genitourinary Diseases), $Billion, 2022-2033
Figure 44: Global Acute Care Syndromic Testing Market (Urinary Tract Infections), $Billion, 2022-2033
Figure 45: Global Acute Care Syndromic Testing Market (Sexually Transmitted Diseases), $Billion, 2022-2033
Figure 46: Global Acute Care Syndromic Testing Market (Tropical Diseases), $Billion, 2022-2033
Figure 47: Global Acute Care Syndromic Testing Market (Others), $Billion, 2022-2033
Figure 48: Global Acute Care Syndromic Testing Market (by Target)
Figure 49: Global Acute Care Syndromic Testing Market (by Target), Share (%), 2022 and 2033
Figure 50: Global Acute Care Syndromic Testing Market (Bacteria), $Billion, 2022-2033
Figure 51: Global Acute Care Syndromic Testing Market (Gram-Positive Bacteria), $Billion, 2022-2033
Figure 52: Global Acute Care Syndromic Testing Market (Gram-Negative Bacteria), $Billion, 2022-2033
Figure 53: Global Acute Care Syndromic Testing Market (Viruses), $Billion, 2022-2033
Figure 54: Global Acute Care Syndromic Testing Market (Fungi), $Billion, 2022-2033
Figure 55: Global Acute Care Syndromic Testing Market (Parasites), $Billion, 2022-2033
Figure 56: Global Acute Care Syndromic Testing Market (by Sample Type)
Figure 57: Global Acute Care Syndromic Testing Market (by Sample Type), Share (%), 2022 and 2033
Figure 58: Global Acute Care Syndromic Testing Market (Blood), $Billion, 2022-2033
Figure 59: Global Acute Care Syndromic Testing Market (Urine), $Billion, 2022-2033
Figure 60: Global Acute Care Syndromic Testing Market (Biofluids), $Billion, 2022-2033
Figure 61: Global Acute Care Syndromic Testing Market (Saliva), $Billion, 2022-2033
Figure 62: Global Acute Care Syndromic Testing Market (Sputum), $Billion, 2022-2033
Figure 63: Global Acute Care Syndromic Testing Market (Stool), $Billion, 2022-2033
Figure 64: Global Acute Care Syndromic Testing Market (Swabs), $Billion, 2022-2033
Figure 65: Global Acute Care Syndromic Testing Market (Genital Swab), $Billion, 2022-2033
Figure 66: Global Acute Care Syndromic Testing Market (Nasopharyngeal Swabs), $Billion, 2022-2033
Figure 67: Global Acute Care Syndromic Testing Market (Other Sample Types), $Billion, 2022-2033
Figure 68: Global Acute Care Syndromic Testing Market (by End User)
Figure 69: Global Acute Care Syndromic Testing Market (by End User), Share (%), 2022 and 2033
Figure 70: Global Acute Care Syndromic Testing Market (Hospitals), $Billion, 2022-2033
Figure 71: Global Acute Care Syndromic Testing Market (Clinical and Diagnostic Laboratories), $Billion, 2022-2033
Figure 72: Global Acute Care Syndromic Testing Market (Research and Academic Institutions), $Billion, 2022-2033
Figure 73: Global Acute Care Syndromic Testing Market (Other End Users), $Billion, 2022-2033
Figure 74: Global Acute Care Syndromic Testing Market Snapshot (by Region)
Figure 75: Global Acute Care Syndromic Testing Market (by Region), $Billion, 2022-2033
Figure 76: North America Acute Care Syndromic Testing Market, $Billion, 2022-2033
Figure 77: North America Acute Care Syndromic Testing Market (by End User), $Billion, 2023-2033
Figure 78: North America Acute Care Syndromic Testing Market (by Country), $Billion, 2022-2033
Figure 79: Top Five Infectious Diseases in the U.S., 2019
Figure 80: U.S. Acute Care Syndromic Testing Market, $Billion, 2022-2033
Figure 81: Canada Acute Care Syndromic Testing Market, $Billion, 2022-2033
Figure 82: Asia-Pacific Acute Care Syndromic Testing Market, $Billion, 2022-2033
Figure 83: Asia-Pacific Acute Care Syndromic Testing Market (by End User), $Billion, 2022-2033
Figure 84: Asia-Pacific Acute Care Syndromic Testing Market (by Country), $Million, 2022-2033
Figure 85: Reported Cases of Top 5 Infectious Diseases, China, 2020
Figure 86: China Acute Care Syndromic Testing Market, $Million, 2022-2033
Figure 87: Japan Acute Care Syndromic Testing Market, $Million, 2022-2033
Figure 88: India Acute Care Syndromic Testing Market, $Million, 2022-2033
Figure 89: Incidence of the Most Common Infectious Diseases in Australia, 2021
Figure 90: Australia Acute Care Syndromic Testing Market, $Million, 2022-2033
Figure 91: South Korea Acute Care Syndromic Testing Market, $Million, 2022-2033
Figure 92: Rest-of-Asia-Pacific Acute Care Syndromic Testing Market, $Million, 2022-2033
Figure 93: Europe Acute Care Syndromic Testing Market, $Billion, 2022-2033
Figure 94: Europe Acute Care Syndromic Testing Market (by End User), $Billion, 2023-2033
Figure 95: Europe Acute Care Syndromic Testing Market (by Country), $Million, 2022-2033
Figure 96: Top 5 Most Common Infectious Diseases in Germany, 2020
Figure 97: Germany Acute Care Syndromic Testing Market, $Million, 2022-2033
Figure 98: France Acute Care Syndromic Testing Market, $Million, 2022-2033
Figure 99: U.K. Acute Care Syndromic Testing Market, $Million, 2022-2033
Figure 100: Italy Acute Care Syndromic Testing Market, $Million, 2022-2033
Figure 101: Spain Acute Care Syndromic Testing Market, $Million, 2022-2033
Figure 102: Rest-of-Europe Acute Care Syndromic Testing Market, $Million, 2022-2033
Figure 103: Latin America Acute Care Syndromic Testing Market, $Billion, 2022-2033
Figure 104: Latin America Acute Care Syndromic Testing Market (by End User), $Million, 2022-2033
Figure 105: Latin America Acute Care Syndromic Testing Market (by Country), $Million, 2022-2033
Figure 106: Brazil Acute Care Syndromic Testing Market, $Million, 2022-2033
Figure 107: Mexico Acute Care Syndromic Testing Market, $Million, 2022-2033
Figure 108: Rest-of-Latin America Acute Care Syndromic Testing Market, $Million, 2022-2033
Figure 109: Rest-of-the-World Acute Care Syndromic Testing Market, $Billion, 2022-2033
Figure 110: Rest-of-the-World Acute Care Syndromic Testing Market (by End User), $Million, 2023-2033
Figure 111: Global Acute Care Syndromic Testing Market, Total Number of Companies Profiled
Figure 112: Abbott Laboratories: Product Portfolio
Figure 113: Abbott Laboratories: Overall Financials, $Million, 2020-2022
Figure 114: Abbott Laboratories: Revenue (by Segment), $Million, 2020-2022
Figure 115: Abbott Laboratories: Revenue (by Region), $Million, 2020-2022
Figure 116: Abbott Laboratories: R&D Expenditure, $Million, 2020-2022
Figure 117: Becton, Dickinson and Company: Product Portfolio
Figure 118: Becton, Dickinson and Company: Overall Financials, $Million, 2020-2022
Figure 119: Becton, Dickinson and Company: Revenue (by Segment), $Million, 2020-2022
Figure 120: Becton, Dickinson and Company: Revenue (by Region), $Million, 2020-2022
Figure 121: Becton, Dickinson and Company: R&D Expenditure, $Million, 2020-2022
Figure 122: Biocartis NV: Product Portfolio
Figure 123: Biocartis NV: Overall Financials, $Million, 2020-2022
Figure 124: Biocartis NV: R&D Expenditure, $Million, 2020-2022
Figure 125: bioM?rieux SA (BioFire Diagnostics): Product Portfolio
Figure 126: bioM?rieux SA (BioFire Diagnostics): Overall Financials, $Million, 2020-2022
Figure 127: bioM?rieux SA (BioFire Diagnostics): Revenue (by Segment), $Million, 2020-2022
Figure 128: bioM?rieux SA (BioFire Diagnostics): Revenue (by Region), $Million, 2020-2022
Figure 129: bioM?rieux SA (BioFire Diagnostics): R&D Expenditure, $Million, 2020-2022
Figure 130: Danaher Corporation (Cepheid, Inc.): Product Portfolio
Figure 131: Danaher Corporation (Cepheid, Inc.): Overall Financials, $Million, 2020-2022
Figure 132: Danaher Corporation (Cepheid, Inc.): Revenue (by Segment), $Million, 2020-2022
Figure 133: Danaher Corporation (Cepheid, Inc.): Revenue (by Region), $Million, 2020-2022
Figure 134: Danaher Corporation (Cepheid, Inc.): R&D Expenditure, $Million, 2020-2022
Figure 135: DiaSorin S.p.A (Luminex Corporation): Product Portfolio
Figure 136: DiaSorin S.p.A (Luminex Corporation): Overall Financials, $Million, 2021 and 2022
Figure 137: DiaSorin S.p.A (Luminex Corporation): Revenue (by Region), $Million, 2021 and 2022
Figure 138: DiaSorin S.p.A (Luminex Corporation): R&D Expenditure, $Million, 2021 and 2022
Figure 139: Eurofins Scientific (Eurofins Viracor): Product Portfolio
Figure 140: Eurofins Scientific (Eurofins Viracor): Overall Financials, $Million, 2020-2022
Figure 141: Eurofins Scientific (Eurofins Viracor): Revenue (by Segment), $Million, 2020-2022
Figure 142: Eurofins Scientific (Eurofins Viracor): Revenue (by Region), $Million, 2020-2022
Figure 143: Karius: Product Portfolio
Figure 144: Laboratory Corporation of America Holdings.: Product Portfolio
Figure 145: Laboratory Corporation of America Holdings.: Overall Financials, $Million, 2020-2022
Figure 146: Laboratory Corporation of America Holdings.: Revenue (by Segment), $Million, 2020-2022
Figure 147: Laboratory Corporation of America Holdings.: Revenue (by Region), $Million, 2020-2022
Figure 148: QIAGEN N.V.: Product Portfolio
Figure 149: QIAGEN N.V.: Overall Financials, $Million, 2020-2022
Figure 150: QIAGEN N.V.: Revenue (by Segment), $Million, 2020-2022
Figure 151: QIAGEN N.V.: Revenue (by Region), $Million, 2020-2022
Figure 152: QIAGEN N.V.: R&D Expenditure, $Million, 2020-2022
Figure 153: QuantuMDx Group Ltd.: Product Portfolio
Figure 154: Seegene, Inc.: Product Portfolio
Figure 155: Seegene, Inc.: Overall Financials, $Million, 2020-2022
Figure 156: Seegene, Inc.: Revenue (by Segment), $Million, 2020-2022
Figure 157: Seegene, Inc.: Revenue (by Region), $Million, 2020-2022
Figure 158: Seegene, Inc.: R&D Expenditure, $Million, 2020-2022
Figure 159: Siemens Healthineers AG: Product Portfolio
Figure 160: Siemens Healthineers AG: Overall Financials, $Million, 2020-2022
Figure 161: Siemens Healthineers AG: Revenue (by Segment), $Million, 2020-2022
Figure 162: Siemens Healthineers AG: Revenue (by Region), $Million, 2020-2022
Figure 163: Siemens Healthineers AG: R&D Expenditure, $Million, 2020-2022
Figure 164: SpeeDX: Product Portfolio
Figure 165: Thermo Fisher Scientific Inc.: Product Portfolio
Figure 166: Thermo Fisher Scientific Inc.: Overall Financials, $Million, 2020-2022
Figure 167: Thermo Fisher Scientific Inc.: Revenue (by Segment), $Million, 2020-2022
Figure 168: Thermo Fisher Scientific Inc.: Revenue (by Region), $Million, 2020-2022
Figure 169: Thermo Fisher Scientific Inc.: R&D Expenditure, $Million, 2020-2022
List of Tables
Table 1: Acute Care Syndromic Testing Product Mapping Analysis (by Disease Type)
Table 2: Global Acute Care Syndromic Testing Market: Impact Analysis
Table 3: Key Questions Answered in the Report
Table 4: Product Benchmarking of Acute Care Syndromic Testing Panels
Table 5: Likert Scale
Table 6: Impact Analysis of Market Drivers
Table 7: Impact Analysis of Market Challenges
Table 8: Popular Assays and Their Turnaround Times
Table 9: Acute Care Syndromic Testing Product Mapping Analysis (by Disease Type)
Table 10: List of FDA-Cleared Upper Respiratory Tract Syndromic Panels
Table 11: Common Upper Tract Respiratory Infections Panels and Key Pathogens being Tested
Table 12: List of FDA-Cleared Lower Respiratory Tract Syndromic Panels
Table 13: Common Gastrointestinal Diseases Panels and Key Pathogens being Tested
Table 14: Common Genitourinary Diseases Panels and Key Pathogens being Tested
Table 15: Common Other Diseases Panels and Key Pathogens being Tested
Table 16: Global Acute Care Syndromic Testing Ecosystem Active Players